| Name | Title | Contact Details |
|---|---|---|
Danny Smith |
Vice President of Research and Development | Profile |
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Rising Pharmaceuticals is an industry leader in marketing and distributing innovative branded and multi-source prescription and over-the-counter pharmaceutical products.
DRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sauflon Pharmaceuticals is a Hicksville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.